HAMPTON, UK, March 28, 2024 / Biotech Newswire / -- Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA™) technology and leaders in enzymatic DNA production, is delighted to announce that it has been awarded a tender to deliver enzymatic DNA as part of CPI’s tender process for the establishment of its RNA Centre of Excellence.
CPI, a leading technology innovation centre in the UK, has selected Touchlight to supply research and GMP-grade enzymatic DNA for the development and manufacture of RNA therapeutics and vaccines. With Touchlight’s dbDNA platform already used in two clinical studies as a critical starting material for mRNA production, Touchlight will contribute its expertise and cutting-edge technology to facilitate the development and scale-up of novel RNA therapeutics.
The selection of Touchlight as a supplier for enzymatic DNA underscores the company’s reputation for delivering high-quality DNA across applications in the genetic medicines industry, including in viral vector production, mRNA, genome editing and DNA vaccines. Touchlight’s dbDNA offers unparalleled advantages in terms of scalability, quality, and safety, making it an ideal choice to enable CPI’s RNA Centre of Excellence.
For high resolution please click the image.
Karen Fallen, CEO of Touchlight said “We’re excited to support CPI and its partners in the development and manufacture of mRNA products. CPI’s RNA Centre of Excellence promises to be a crucial part of the mRNA supply chain in the UK, helping to advance mRNA vaccines and therapies more quickly.”
Julie Anderson, Head of RNA Centre of Excellence at CPI said: "It is important for CPI to include access to the high-quality DNA templates produced by Touchlight for our clients for the development and manufacture of RNA therapeutics. We are impressed by the capabilities of the Touchlight team and are looking forward to including their synthetic templates in the development of our partners' RNA medicines."
About Touchlight
Touchlight is a privately-owned innovation-driven CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced doggybone DNA (dbDNA™) to enable the development of genetic medicines. Touchlight provides rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through clinical development, to licencing and tech transfer for use in-house.
About CPI
We're a pioneering social enterprise that accelerates the development, scale-up and commercialisation of smart AgriFoodTech, energy storage, HealthTech, materials, and pharma innovations. Through our incredible innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future.
Developing next-generation medicine manufacturing innovations to deliver tomorrow's vaccines and therapeutics. We offer world-leading facilities and expertise in small molecules, biologics, oligonucleotides, and complex medicines to accelerate drug development and scale-up. We host the largest pool of RNA biomanufacturing experts in the UK and offer complementary drug delivery systems like lipid nanoparticles.
We're creating agile, efficient, and sustainable supply chains by convening actors across the pharma industry ecosystem in a pre-competitive space and boosting the adoption of industry 4.0 advanced processes and digitisation.
We're a pioneering social enterprise that accelerates the development, scale-up and commercialisation of smart AgriFoodTech, energy storage, HealthTech, materials, and pharma innovations. Through our incredible innovation experts and infrastructure, we look beyond the obvious to transform healthcare and drive towards a sustainable future.
As a trusted partner of industry, academia, government, entrepreneurs, and the investment community, we connect the dots within the innovation ecosystem to make great ideas and inventions a reality. We believe by working together we can build a better collective future, and as part of the High Value Manufacturing Catapult, we facilitate access to world-class organisations to deliver transformation across industries and landscapes. Creating lasting global impact from the North of England and Scotland, we invest in people and disruptive technologies to invigorate economies, create circular supply chains and make our world a better place.
Contact
Touchlight
Karen Fallen, Chief Executive Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
+44 20 8481 9200
Keywords: Manufacturing Industry; Vaccines, DNA; RNA, Messenger; Gene Editing; DNA; RNA; Technology; United Kingdom; Touchlight; Enzymatic dbDNA; CPI; RNA Centre of Excellence; Genetic medicines; mRNA; Vaccines; Genetic medicine industry; Clinical studies; Viral vector production; Genome editing; DNA vaccines; Karen Fallen; Julie Anderson; London, U.K.; CDMO (Contract Development and Manufacturing Organization); Doggybone DNA (dbDNA™); GMP-grade DNA; mRNA products; Genetic medicine manufacturing; High-quality DNA; RNA therapeutics; Oligonucleotides; Drug delivery systems; Circular supply chains
Published by Biotech Newswire